Figure 4. Histograms showing EDH evoked by SLIGRL (20 µM) in rat MCAs that are able to synthesise NO but treated with the TP receptor agonist, U46619 (50–100 nM).

Also shown is the effect of the HMG-CoA reductase inhibitor simvastatin at either 100 nM (A) or 1 µM (B) on EDH and the effect of blocking K_Ca3.1 alone (TRAM-34, 1 µM), in the subsequent presence of blockade of both K_Ca2.3 (apamin 100 nM) and K_Ca3.1 as well as the combined of blockade of K_Ca1.1 (iberiotoxin 100 nM), K­_Ca2.3 and K_Ca3.1. *P<0.05 indicates a significant difference from control using one way ANOVA with Tukey’s post-test, n = 4–7. ^φP<0.05 indicates a significant difference from simvastatin (100 nM or 1 µM) as determined by one-way ANOVA with Tukey’s post-test, n = 4–7.